-
公开(公告)号:US20120046290A1
公开(公告)日:2012-02-23
申请号:US11932548
申请日:2007-10-31
申请人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Holger Paulsen , Bernd Riedl , William J. Scott , Roger A. Smith , Jill Wood , Holia Hatoum-Mokdad , Wendy Lee , Aniko Redman , Jeffrey Johnson , Robert Sibley
发明人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Holger Paulsen , Bernd Riedl , William J. Scott , Roger A. Smith , Jill Wood , Holia Hatoum-Mokdad , Wendy Lee , Aniko Redman , Jeffrey Johnson , Robert Sibley
IPC分类号: A61K31/42 , A61K31/428 , A61K31/422 , A61K31/497 , A61K31/506 , A61K31/4709 , A61K31/5377 , C07D261/14 , C07D231/40 , A61K31/415 , A61P29/00 , A61P19/02 , A61P19/10 , A61P11/06 , A61P1/00 , A61P31/00 , A61K31/4439
CPC分类号: C07D231/40 , A61K31/381 , A61K31/415 , A61K31/4155 , A61K31/416 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/426 , A61K31/428 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/506 , C07D261/14 , Y02A50/411
摘要: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
-
2.Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors 有权
标题翻译: 羟基,ω-羧基芳基取代的二苯基脲和其衍生物作为raf激酶抑制剂公开(公告)号:US07528255B2
公开(公告)日:2009-05-05
申请号:US10071248
申请日:2002-02-11
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , William Scott , Roger Smith , Jill Wood
IPC分类号: C07D211/72 , C07D213/62 , C07D213/78
CPC分类号: C07D295/192 , A61K31/17 , A61K31/18 , A61K31/24 , A61K31/341 , A61K31/40 , A61K31/4035 , A61K31/44 , A61K31/4439 , A61K31/4453 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/5377 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/36 , C07C275/40 , C07C311/29 , C07C317/22 , C07D209/46 , C07D209/48 , C07D209/50 , C07D213/75 , C07D213/80 , C07D213/81 , C07D295/073 , C07D295/12 , C07D295/13 , C07D295/135 , C07D295/18 , C07D401/12 , C07F7/1804
摘要: The invention relates to the use of a group of aryl ureas in treating raf mediated diseases and pharmaceutical compositions for use in such therapy of the formula wherein, Y is NHR Hal is chlorine or bromine, R is H, CH3 or CH2OH, and X1 to X7 are each, independently, H, OH or —OC(O)C1-C4 alkyl, or a salt purified stereoisomer thereof, wherein at least one of X1 to X7 is OH or —OC(O)C1-C4 alkyl.
摘要翻译: 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途以及用于下列治疗的药物组合物:其中Y是NHR Hal是氯或溴,R是H,CH3或CH2OH,X1至 X 7各自独立地为H,OH或-OC(O)C 1 -C 4烷基或其盐纯化的立体异构体,其中X 1至X 7中的至少一个为OH或-OC(O)C 1 -C 4烷基。
-
3.Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors 审中-公开
标题翻译: ω-羧酰基取代的二苯脲作为Raf激酶抑制剂公开(公告)号:US20080153823A1
公开(公告)日:2008-06-26
申请号:US11956111
申请日:2007-12-13
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert Sibley
IPC分类号: A61K31/5377 , C07D211/70 , C07D209/36 , C07D413/12 , A61K31/44 , A61K31/4965 , A61P43/00 , A61K31/497 , A61K31/4035 , C07D401/12 , C07D241/02
CPC分类号: C07D209/48 , C07C251/48 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/36 , C07C275/40 , C07C311/29 , C07C317/22 , C07D207/09 , C07D209/46 , C07D213/74 , C07D213/75 , C07D213/79 , C07D213/81 , C07D213/82 , C07D295/12 , C07D295/13 , C07D295/135 , C07D295/18 , C07D295/192 , C07D307/14 , C07D401/12
摘要: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途,以及用于此类治疗的药物组合物。
-
4.Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors 审中-公开
标题翻译: ω-羧酰基取代的二苯基脲作为Raf Kinease抑制剂公开(公告)号:US20080032979A1
公开(公告)日:2008-02-07
申请号:US11845595
申请日:2007-08-27
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , Scott William , Roger Smith , Jill Wood , Mary-Katherine Monahan , Reink Natero , Joel Renick , Robert Sibley
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy Lowinger , Scott William , Roger Smith , Jill Wood , Mary-Katherine Monahan , Reink Natero , Joel Renick , Robert Sibley
IPC分类号: A61K31/4035 , A61K31/17 , A61K31/44 , A61K31/5377 , A61P35/00 , C07C275/28 , C07D209/48 , C07D213/62 , C07D413/12
CPC分类号: C07C275/36 , A61K31/17 , A61K31/18 , A61K31/24 , A61K31/341 , A61K31/40 , A61K31/4035 , A61K31/44 , A61K31/4439 , A61K31/4453 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/5377 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/40 , C07C311/29 , C07C317/22 , C07D209/46 , C07D209/48 , C07D209/50 , C07D213/75 , C07D213/80 , C07D213/81 , C07D213/82 , C07D295/073 , C07D295/12 , C07D295/13 , C07D295/135 , C07D295/18 , C07D295/192 , C07D401/12 , C07D413/12 , C07F7/1804
摘要: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途,以及用于此类治疗的药物组合物。
-
公开(公告)号:US20050256174A1
公开(公告)日:2005-11-17
申请号:US11149332
申请日:2005-06-10
申请人: Jill Wood , Hanno Wild , Daniel Rogers , John Lyons , Michael Katz , Yolanda Caringal , Robert Dally , Wendy Lee , Roger Smith , Cheri Blum
发明人: Jill Wood , Hanno Wild , Daniel Rogers , John Lyons , Michael Katz , Yolanda Caringal , Robert Dally , Wendy Lee , Roger Smith , Cheri Blum
IPC分类号: A61K31/38 , A61K31/381 , A61K31/416 , A61K31/433 , C07D207/34 , C07D307/68 , C07D333/38 , C07D333/42 , C07D409/00 , C07D409/12 , C07D417/12
CPC分类号: C07D207/34 , C07D307/68 , C07D333/38 , C07D409/12 , C07D417/12 , C07D471/04
摘要: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
摘要翻译: 治疗由raf激酶介导的肿瘤与取代的脲化合物及其化合物本身的方法。
-
6.SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS 有权
标题翻译: SULFONE取代的2,3-二羟基喹喔啉[1,2-C]喹唑啉衍生物有助于治疗高血压疾病和疾病与血管发生公开(公告)号:US20110190281A1
公开(公告)日:2011-08-04
申请号:US12812911
申请日:2009-01-13
申请人: Martin Hentemann , William Scott , Jill Wood , Jeffrey Johnson , Aniko Redman , Ann-Marie Bullion , Leatte Guernon
发明人: Martin Hentemann , William Scott , Jill Wood , Jeffrey Johnson , Aniko Redman , Ann-Marie Bullion , Leatte Guernon
IPC分类号: A61K31/541 , C07D487/04 , A61K31/519 , C12N9/99 , C07D413/14 , A61K31/5377 , C07D417/14 , A61P35/00
CPC分类号: A61K45/06 , A61K31/519 , A61K31/541 , A61K2300/00 , C07D487/04
摘要: This invention relates to novel sulfone 2I3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis mediated disorders, as a sole agent or in combination with other active ingredients.
摘要翻译: 本发明涉及新的砜2I3-二氢咪唑并[1,2-c]喹唑啉化合物,含有这些化合物的药物组合物,以及这些化合物或组合物用于磷脂酰肌醇-3-激酶(PI3K)抑制和治疗与磷脂酰肌醇-3 - 激酶(PI3K)活性,特别是治疗高增殖和/或血管发生介导的病症,作为唯一的药剂或与其它活性成分组合。
-
7.Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions 审中-公开
标题翻译: 喹诺酮羧酸衍生物治疗过度增生症状公开(公告)号:US20070213339A1
公开(公告)日:2007-09-13
申请号:US10594978
申请日:2005-03-31
申请人: Uday Khire , Xiao-Gao Liu , Dhanapalan Nagarathnam , Jill Wood , Lei Wang , Donglei Liu , Jin Zhao , Leatte Guernon , Lei Zhang
发明人: Uday Khire , Xiao-Gao Liu , Dhanapalan Nagarathnam , Jill Wood , Lei Wang , Donglei Liu , Jin Zhao , Leatte Guernon , Lei Zhang
IPC分类号: A61K31/506 , A61K31/496 , C07D403/14
CPC分类号: C07D215/56 , C07D401/12 , C07D401/14
摘要: Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.
摘要翻译: 式(I)的喹诺酮羧酸衍生物,其中Ar是任选取代的苯基,吡啶基或嘧啶基,取代基R 1,R 4,R 4, 10,R 11,R 19和R 20如说明书中所定义,含有它们的药物组合物和方法 将其用于治疗过度增殖性疾病如癌症的方法。
-
8.Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas 失效
标题翻译: 使用喹啉基,异喹啉基或吡啶基脲来抑制RAF激酶公开(公告)号:US20060019990A1
公开(公告)日:2006-01-26
申请号:US11158048
申请日:2005-06-22
申请人: Jacques Dumas , Bernd Riedl , Uday Khire , Robert Sibley , Holia Hatoum-Mokdad , Mary-Katherine Monahan , David Gunn , Timotthy Lowinger , William Scott , Roger Smith , Jill Wood
发明人: Jacques Dumas , Bernd Riedl , Uday Khire , Robert Sibley , Holia Hatoum-Mokdad , Mary-Katherine Monahan , David Gunn , Timotthy Lowinger , William Scott , Roger Smith , Jill Wood
IPC分类号: A61K31/4709 , A61K31/444 , C07D401/02
CPC分类号: C07D213/40
摘要: The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
摘要翻译: 本发明涉及一组喹啉基,异喹啉基和吡啶基脲,它们在治疗raf介导的疾病中的用途,以及含有用于这种治疗的这些尿素的药物组合物。
-
9.Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis 有权
标题翻译: 用于治疗高增殖性疾病和血管生成疾病的砜取代的2,3-二氢咪唑并[1,2-C]喹唑啉衍生物公开(公告)号:US08859572B2
公开(公告)日:2014-10-14
申请号:US12812911
申请日:2009-01-13
申请人: Martin F. Hentemann , William Scott , Jill Wood , Jeffrey Johnson , Aniko Redman , Ann-Marie Bullion , Leatte Guernon
发明人: Martin F. Hentemann , William Scott , Jill Wood , Jeffrey Johnson , Aniko Redman , Ann-Marie Bullion , Leatte Guernon
IPC分类号: A61K31/519 , A61K45/06 , A61K31/541 , C07D487/04
CPC分类号: A61K45/06 , A61K31/519 , A61K31/541 , A61K2300/00 , C07D487/04
摘要: This invention relates to novel sulfone 2I3-dihydroimidazo[1 l2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis mediated disorders, as a sole agent or in combination with other active ingredients.
摘要翻译: 本发明涉及新的砜2I3-二氢咪唑并[11l-c]喹唑啉化合物,含有这些化合物的药物组合物以及这些化合物或组合物用于磷脂酰肌醇-3-激酶(PI3K)的用途,其用于抑制和治疗与磷脂酰肌醇-3- 激酶(PI3K)活性,特别是治疗高增殖和/或血管发生介导的病症,作为唯一的药剂或与其它活性成分组合。
-
10.1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders 审中-公开
标题翻译: 1,8-萘啶衍生物及其用于治疗糖尿病和相关疾病的用途公开(公告)号:US20060189609A1
公开(公告)日:2006-08-24
申请号:US11409536
申请日:2006-04-21
申请人: Yamin Wang , William Bullock , David Gunn , Qingjie Liu , Sidney Liang , Donglei Liu , Steven Magnuson , Tindy Li , Eric Mull , Jill Wood , Ning Qi
发明人: Yamin Wang , William Bullock , David Gunn , Qingjie Liu , Sidney Liang , Donglei Liu , Steven Magnuson , Tindy Li , Eric Mull , Jill Wood , Ning Qi
IPC分类号: A61K31/5377 , A61K31/496 , A61K31/4745 , C07D471/02
CPC分类号: A61K45/06 , A61K31/44 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D471/04 , A61K2300/00
摘要: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
摘要翻译: 本发明一般涉及下式的萘啶衍生物,其中U,X,Y和Z中的一个为氮,其余为C-R,其中R为氢或取代基。 更具体地,本发明涉及1,8-萘啶衍生物和含有这些衍生物的药物组合物。 本发明的方法包括施用本发明的萘啶衍生物用于治疗糖尿病和相关疾病。
-
-
-
-
-
-
-
-
-